Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter F Thall

Showing results (31-40 of 190) with videos related to

Pageof 19
Sort By:
Biometrics|September 4, 2007
Determining the effective sample size of a parametric priorSatoshi Morita, Peter F Thall, Peter Müller
Biometrics|October 17, 2014
Bayesian nonparametric estimation of targeted agent effects on biomarker change to predict clinical outcomeRebecca Graziani, Michele Guindani, Peter F Thall
Cancers|October 14, 2023
Interpreting Randomized Controlled TrialsPavlos Msaouel, Juhee Lee, Peter F Thall
Bayesian Analysis|July 16, 2021
A Phase I-II Basket Trial Design to Optimize Dose-Schedule Regimes Based on Delayed OutcomesRuitao Lin, Peter F Thall, Ying Yuan
Applied Stochastic Models in Business and Industry|December 5, 2017
Clinical Trial Design as a Decision ProblemPeter Müller, Yanxun Xu, Peter F Thall
Statistics & Probability Letters|July 30, 2014
A Modified Adaptive Lasso for Identifying Interactions in the Cox Model with the Heredity ConstraintLu Wang, Jincheng Shen, Peter F Thall
Bayesian Analysis|November 1, 2013
Prior Effective Sample Size in Conditionally Independent Hierarchical ModelsSatoshi Morita, Peter F Thall, Peter Müller
Cancers|July 2, 2021
Making Patient-Specific Treatment Decisions Using Prognostic Variables and Utilities of Clinical OutcomesPavlos Msaouel, Juhee Lee, Peter F Thall
Statistics in Medicine|April 8, 2020
A phase I-II design based on periodic and continuous monitoring of disease status and the times to toxicity and deathJuhee Lee, Peter F Thall, Pavlos Msaouel
Biometrics|February 16, 2024
A generalized phase 1-2-3 design integrating dose optimization with confirmatory treatment comparisonYong Zang, Peter F Thall, Ying Yuan
Pageof 19

Showing results (31-40 of 190) with videos related to

Sort By:
Pageof 19
Biometrics|September 4, 2007
Determining the effective sample size of a parametric priorSatoshi Morita, Peter F Thall, Peter Müller
Biometrics|October 17, 2014
Bayesian nonparametric estimation of targeted agent effects on biomarker change to predict clinical outcomeRebecca Graziani, Michele Guindani, Peter F Thall
Cancers|October 14, 2023
Interpreting Randomized Controlled TrialsPavlos Msaouel, Juhee Lee, Peter F Thall
Bayesian Analysis|July 16, 2021
A Phase I-II Basket Trial Design to Optimize Dose-Schedule Regimes Based on Delayed OutcomesRuitao Lin, Peter F Thall, Ying Yuan
Applied Stochastic Models in Business and Industry|December 5, 2017
Clinical Trial Design as a Decision ProblemPeter Müller, Yanxun Xu, Peter F Thall
Statistics & Probability Letters|July 30, 2014
A Modified Adaptive Lasso for Identifying Interactions in the Cox Model with the Heredity ConstraintLu Wang, Jincheng Shen, Peter F Thall
Bayesian Analysis|November 1, 2013
Prior Effective Sample Size in Conditionally Independent Hierarchical ModelsSatoshi Morita, Peter F Thall, Peter Müller
Cancers|July 2, 2021
Making Patient-Specific Treatment Decisions Using Prognostic Variables and Utilities of Clinical OutcomesPavlos Msaouel, Juhee Lee, Peter F Thall
Statistics in Medicine|April 8, 2020
A phase I-II design based on periodic and continuous monitoring of disease status and the times to toxicity and deathJuhee Lee, Peter F Thall, Pavlos Msaouel
Biometrics|February 16, 2024
A generalized phase 1-2-3 design integrating dose optimization with confirmatory treatment comparisonYong Zang, Peter F Thall, Ying Yuan
Pageof 19